Insulin Analogues (Insulin Detemir and Insulin Aspart) Versus Traditional Human Insulins (NPH Insulin Regular Human Insulin) in Basal Bolus Therapy for Patients with Type-I Diabetes Mellitus

Muhammad Hamza Zaheer; Muhammad Adnan Manzar; Bilal Ahmed; Roshaan Tahir; Muhammad Hamza Qureshi; Shawnze Akhtar

doi:10.51253/pafmj.v76iSUPPL-9.8997

Authors

Muhammad Hamza Zaheer Department of General Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Muhammad Adnan Manzar Department of Rheumatology, Combined Military Hospital Lahore/National University of Medical Sciences (NUMS) Pakistan
Bilal Ahmed Department of Endocrinology, National University of Medical Sciences (NUMS) Pakistan
Roshaan Tahir Department of General Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Muhammad Hamza Qureshi Medical Officer, Mayo Hospital, Lahore Pakistan
Shawnze Akhtar Medical Officer, Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-9.8997

Keywords:

Diabetic Control, Human Insulin, Insulin analog, Type-I DM

Abstract

Objective: To compare the effect of Insulin analogues (Insulin Detemir and Insulin Aspart) versus Traditional Human Insulins (NPH Insulin Regular Human Insulin) in basal bolus therapy for patients with Type-I Diabetes Mellitus.

Study Design: Comparative cross-sectional study.

Place and Duration of Study: Department of Medicine, Pak Emirates Military Hospital, Rawalpindi Pakistan, from Jun 2021 to Jun 2022.

Methodology: The sample population comprised of 125 type I diabetes mellitus patients which were diagnosed in our department and managed. Patients were divided into two Groups via lottery method. Group A received the Insulin analogues (Insulin Detemir and Insulin Aspart) while Group B received the Human Insulins (NPH Insulin Regular Human Insulin). Glycosylated hemoglobin, weight gain, hypoglycemic episodes and compliance were compared in both Groups at the end of three months.

Results: Out of 125 patients of Type-I diabetes mellitus included in the study, 85(68%) were male while 40(32%) were female. Mean age of the patients was 14.93±3.75 years. 62(49.6%) patients were managed with insulin analogue while 63(50.4%) were managed with human insulin. Statistical analysis revealed that glycemic control (p-value-0.001) was better in patients who took insulin analogues. Hypoglycemic episodes were also significantly less (p-value-0.002) in patients who took insulin analogues.

Conclusion: Insulin analogues (Insulin Detemir and Insulin Aspart) emerged as better treatment option for patients of Type-I diabetes Mellitus when compared to Traditional Human Insulins (NPH Insulin Regular Human Insulin) in our study participants.

Downloads

Download data is not yet available.

References

1. Uloko AE, Musa BM, Ramalan MA. Prevalence and Risk Factors for Diabetes Mellitus in Nigeria: A Systematic Review and Meta-Analysis. Diabetes Ther 2018; 9(3): 1307-1316.

2. Bullard KM, Cowie CC, Lessem SE. Prevalence of Diagnosed Diabetes in Adults by Diabetes Type - United States, 2016. MMWR Morb Mortal Wkly Rep 2018; 67(12): 359-361.

http://doi.org/5585/mmwr.mm6712a2

3. Al Mansari A, Obeid Y, Islam N. GOAL study: clinical and non-clinical predictive factors for achieving glycemic control in people with type 2 diabetes in real clinical practice. BMJ Open Diabetes Res Care 2018; 6(1): e000519.

http://doi.org/10.1136/bmjdrc-2018-000519

4. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomark Insights 2016; 11: 95-104.

http://doi.org/10.4137/BMI.S38440

5. Shomali M. Diabetes treatment in 2025: can scientific advances keep pace with prevalence?. Ther Adv Endocrinol Metab 2012; 3(5): 163-173.

6. Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE. The Evolution of Insulin and How it Informs Therapy and Treatment Choices. Endocr Rev 2020; 41(5): 733–755.

http://doi.org/10.1210/endrev/bnaa015

7. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47(4): 622-629.

http://doi.org/10.1007/s00125-004-1365-z

8. Margaritidis C, Karlafti E, Kotzakioulafi E, Kantartzis K, Tziomalos K, Kaiafa G, et al. Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring. J Clin Med 2021; 10(9): 1982.

http://doi.org/10.3390/jcm10091982

9. Kristensen PL, Tarnow L, Bay C, Nørgaard K, Jensen T, Parvinget H-H et al. Comparing effects of insulin analogues and human insulin on nocturnal glycaemia in hypoglycaemia-prone people with Type 1 diabetes. Diabet Med 2017; 34(5): 625-631.

http://doi.org/10.1111/dme.13317

10. Hassan MI, Aamir AH, Miyan Z, Siddiqui LA, Mahmood S, Vohra EA. Switch from biphasic human insulin 30 to biphasic insulin aspart 30 in Pakistani subjects. J Pak Med Assoc 2013; 63(10): 1290-1294.

11. Bardisi WM, Khorsheed MM, Magliah F, Magliah AF. Efficacy of insulin analogues in diabetic patients attending primary care centers. Saudi Med J. 2015; 36(7): 829-833.

http://doi.org/10.15537/smj.2015.7.11409

12. Lim WY, Ma S, Heng D, Tai ES, Khoo CM, Loh TP. Screening for diabetes with HbA1c: Test performance of HbA1c compared to fasting plasma glucose among Chinese, Malay and Indian community residents in Singapore. Sci Rep 2018; 8(1): 12419.

http://doi.org/ 10.1038/s41598-018-29998-z

13. Silver B, Ramaiya K, Andrew SB, Fredrick O, Bajaj S, Kalra S, et al. EADSG Guidelines: Insulin Therapy in Diabetes. Diabetes Ther 2018; 9(2): 449-492.

http://doi.org/10.1007/s13300-018-0384-6

14. Haase CL, Eriksen KT, Lopes S, Satylganova A, Schnecke V, McEwan P. Body mass index and risk of obesity-related conditions in a cohort of 2.9 million people: Evidence from a UK primary care database. Obes Sci Pract 2020; 7(2): 137-147.

http://doi.org/10.1002/osp4.474

15. Laranjeira FO, de Andrade KRC, Figueiredo ACMG, Silva EN, Pereira MG. Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials. PLoS One 2018; 13(4): e0194801.

http://doi.org/10.1371/journal.pone.0194801

16. Melo KFS, Bahia LR, Pasinato B, Porfirio GJM, Martimbianco AL, Riera R, et al. Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr 2019; 11: 2.

http://doi.org/10.1186/s13098-018-0397-3

17. Zhou Y, Takagi T, Tian YS. Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis [published correction appears in Naunyn Schmiedebergs Arch Pharmacol. 2021 Aug 19;:]. Naunyn Schmiedebergs Arch Pharmacol 2021; 394(10): 2091-2101.

http://doi.org/ 10.1007/s00210-021-02128-9

18. Yamada S, Watanabe M, Kitaoka A, Shiono K, Atsuda K, Tsukamoto Y, et al. Switching from premixed human insulin to premixed insulin lispro: a prospective study comparing the effects on glucose control and quality of life. Intern Med 2007; 46(18): 1513-1517.

http://doi.org/10.2169/internalmedicine.46.0236